Latest Ratios: P/E Ratio -0.3x · EV/EBITDA N/A · ROE -270.8%. (2019–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $2M | $4M | $14M | $49M | $43M | $44M | — | — |
| Enterprise Value | $-7553801782 | $-7552367490 | $10M | $41M | $34M | $31M | — | — |
| P/E Ratio → | -0.27 | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — |
| P/B Ratio | 0.41 | 0.71 | 22.54 | 10.40 | 5.88 | 3.56 | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -270.8% | -270.8% | -534.0% | -243.3% | -122.6% | -168.7% | -261.3% | -723.5% |
| ROA | -138.0% | -138.0% | -243.8% | -170.6% | -106.9% | -154.7% | -159.8% | -234.3% |
| ROIC | — | — | — | — | — | — | — | — |
| ROCE | -275.1% | -275.1% | -534.0% | -243.3% | -122.6% | -169.0% | -257.6% | -723.5% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | 0.02 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1434.18 | -6.03 | -1.60 | -1.25 | -1.04 | -1.15 | -3.03 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — |
Net cash position: cash ($7.6B) exceeds total debt ($0)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.18 | 3.18 | 1.19 | 2.53 | 4.55 | 15.71 | 6.82 | 1.48 |
| Quick Ratio | 3.18 | 3.18 | 1.19 | 2.53 | 4.55 | 15.71 | 6.82 | 1.48 |
| Cash Ratio | 3121.14 | 3121.14 | 1.14 | 2.46 | 4.42 | 15.36 | 6.72 | 1.45 |
| Asset Turnover | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $1M | $851550 | $633600 | $540800 | $510800 | $495800 | $477050 |
Binary clinical trial failure
According to current market data, ACXP trades at a P/B ratio of 0.43, which suggests that investors are heavily discounting the firm's book value due to the binary nature of its clinical-stage pipeline and the persistent lack of commercial revenue generation.
The low P/B multiple relative to broader biotech peers indicates that the market assigns little value to the company's tangible assets, viewing them primarily as a vehicle for R&D expenditure. This valuation level implies that the market is pricing in a high probability of further equity dilution or clinical failure, rather than the potential upside of the ibezapolstat program.
As reported in financial statements, ACXP exhibits consistently negative profitability metrics, with ROE reaching -27.4% in 2026Q1, reflecting the structural reality of a pre-revenue biotechnology firm that must prioritize clinical trial execution over immediate earnings generation.
The absence of gross and operating margins confirms that the firm has not yet transitioned to a commercial model, making traditional profitability analysis largely irrelevant for assessing current performance. Investors should monitor the trend in net losses as a proxy for the efficiency of the company's clinical trial spending rather than as a measure of operational profitability.
Based on reported figures, the current ratio has fluctuated between 1.19 and 3.78 over the last ten quarters, yet this metric provides a misleading sense of security given the company's lack of revenue and the high probability of future dilutive capital raises to fund clinical trials.
While the current ratio appears healthy on the surface, it fails to account for the rapid depletion of cash reserves required to sustain ongoing Phase 3 clinical activities. The volatility in these ratios suggests that the company's liquidity position is highly sensitive to the timing of external financing rounds rather than internal cash generation.
The current ratio is the most commonly misapplied metric for ACXP, as it obscures the firm's fundamental inability to generate internal cash flow and its total reliance on external capital markets to maintain operations, according to an analysis of the company's pre-revenue financial structure.
Using the current ratio to assess solvency in a clinical-stage biotech is misleading because it treats cash as a static buffer rather than a rapidly depleting resource tied to specific clinical milestones. Analysts should instead focus on the 'cash runway' in months, which provides a more accurate assessment of the time remaining before the company must return to the equity markets for survival.
Includes 30+ ratios · 7 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ACXP stock.
Acurx Pharmaceuticals, Inc.'s current P/E ratio is -0.3x. This places it at the 50th percentile of its historical range.
Acurx Pharmaceuticals, Inc.'s return on equity (ROE) is -270.8%. The historical average is -213.3%.
Based on historical data, Acurx Pharmaceuticals, Inc. is trading at a P/E of -0.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.